B
Benjamin M. Ellingson
Researcher at University of California, Los Angeles
Publications - 325
Citations - 11062
Benjamin M. Ellingson is an academic researcher from University of California, Los Angeles. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 47, co-authored 261 publications receiving 8228 citations. Previous affiliations of Benjamin M. Ellingson include Marquette University & UCLA Medical Center.
Papers
More filters
Journal ArticleDOI
Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma.
Timothy F. Cloughesy,Aaron Mochizuki,Joey Orpilla,Willy Hugo,Alexander Lee,Tom B. Davidson,Anthony C. Wang,Benjamin M. Ellingson,Julie A. Rytlewski,Catherine Sanders,Eric S. Kawaguchi,Lin Du,Gang Li,William H. Yong,Sarah C. Gaffey,Adam L. Cohen,Ingo K. Mellinghoff,Eudocia Q. Lee,David A. Reardon,Barbara O’Brien,Nicholas Butowski,Phioanh L. Nghiemphu,Jennifer Clarke,Isabel Arrillaga-Romany,Howard Colman,Thomas Kaley,John de Groot,Linda M. Liau,Patrick Y. Wen,Robert M. Prins +29 more
TL;DR: It is suggested that the neoadjuvant administration of PD-1 blockade enhances both the local and systemic antitumor immune response and may represent a more efficacious approach to the treatment of this uniformly lethal brain tumor.
Journal ArticleDOI
Immunotherapy response assessment in neuro-oncology: a report of the RANO working group.
Hideho Okada,Michael Weller,Raymond Y. Huang,Gaetano Finocchiaro,Mark R. Gilbert,Wolfgang Wick,Benjamin M. Ellingson,Naoya Hashimoto,Ian F. Pollack,Alba A. Brandes,Enrico Franceschi,Christel Herold-Mende,Lakshmi Nayak,Ashok Panigrahy,Whitney B. Pope,Robert M. Prins,John H. Sampson,Patrick Y. Wen,David A. Reardon +18 more
TL;DR: Immunotherapy Response Assessment for Neuro-Oncology (iRANO) criteria based on guidance for the determination of tumour progression outlined by the immune-related response criteria and the RANO working group are described.
Journal ArticleDOI
Consensus recommendations for a standardized Brain Tumor Imaging Protocol in clinical trials
Benjamin M. Ellingson,Martin Bendszus,Martin Bendszus,Jerrold L. Boxerman,Daniel P. Barboriak,Bradley J. Erickson,Marion Smits,Marion Smits,Sarah J. Nelson,Elizabeth R. Gerstner,Elizabeth R. Gerstner,Brian M. Alexander,Gregory V. Goldmacher,Wolfgang Wick,Wolfgang Wick,Michael A. Vogelbaum,Michael A. Vogelbaum,Michael Weller,Evanthia Galanis,Jayashree Kalpathy-Cramer,Lalitha K. Shankar,Paula M. Jacobs,Whitney B. Pope,Dewen Yang,Caroline Chung,Michael V. Knopp,Soonme Cha,Martin J. van den Bent,Martin J. van den Bent,Susan M. Chang,W. K. Alfred Yung,Timothy F. Cloughesy,Patrick Y. Wen,Mark R. Gilbert,Mark R. Gilbert,Andrew Whitney,David Sandak,Al Musella,Chas Haynes,Max Wallace,David Arons,Ann E Kingston +41 more
TL;DR: The current document outlines consensus recommendations for a standardized Brain Tumor Imaging Protocol (BTIP), along with the scientific and practical justifications for these recommendations, resulting from a series of discussions between various experts involved in aspects of neuro-oncology neuroimaging for clinical trials.
Journal ArticleDOI
Evidence for sequenced molecular evolution of IDH1 mutant glioblastoma from a distinct cell of origin.
Albert Lai,Samir Kharbanda,Whitney B. Pope,Anh Tran,Orestes E. Solis,Franklin Peale,William F. Forrest,Kanan Pujara,Jose Carrillo,Ajay Pandita,Benjamin M. Ellingson,Chauncey W. Bowers,Robert Soriano,Nils Ole Schmidt,Sankar Mohan,William H. Yong,Somasekar Seshagiri,Zora Modrusan,Zhaoshi Jiang,Kenneth Aldape,Paul S. Mischel,Linda M. Liau,Cameron Escovedo,Weidong Chen,Phioanh L. Nghiemphu,C. David James,Michael D. Prados,Manfred Westphal,Katrin Lamszus,Timothy F. Cloughesy,Heidi S. Phillips,Heidi S. Phillips +31 more
TL;DR: Although histologically similar, GBMs arising with and without IDH1(R132MUT) appear to represent distinct disease entities that arise from separate cell types of origin as the result of largely nonoverlapping sets of molecular events.
Journal ArticleDOI
Relationship between Tumor Enhancement, Edema, IDH1 Mutational Status, MGMT Promoter Methylation, and Survival in Glioblastoma
Jose Carrillo,Albert Lai,Phioanh L. Nghiemphu,Hyun J. Kim,Heidi S. Phillips,Samir Kharbanda,Parham Moftakhar,S. Lalaezari,William H. Yong,Benjamin M. Ellingson,Timothy F. Cloughesy,Whitney B. Pope +11 more
TL;DR: Investigating the ability of imaging correlates to serve as noninvasive biomarkers for these molecularly defined GBM subtypes found that imaging features are potentially predictive of IDH1 mutational status but were poorly correlated with MGMT promoter methylation.